Tenofovir Alafenamide Hemifumarate Introduction

Tenofovir Alafenamide Hemifumarate Specification

Tenofovir Alafenamide Hemifumarate Key Features

1. High Potency at Low Doses

   • TAF is efficiently converted into the active metabolite Tenofovir Diphosphate within cells, inhibiting viral reverse transcriptase and blocking viral replication.

   • Clinically effective at 1/10 the dose of TDF (e.g., 25mg vs. 300mg) while maintaining comparable efficacy.

2. Improved Safety Profile

   • Reduces kidney and bone-related side effects (e.g., osteoporosis, renal impairment), making it suitable for long-term therapy.

Tenofovir Alafenamide Hemifumarate Applications

TAF vs. TDF Comparison